{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.4","value":"5.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Volume of distribution at steady state (Vss) of the AFM13. Geometric coefficient of variation is given in percentages.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).","id":"OG000","title":"Cohort A"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetic set (PK) consists of subjects who had at least received one dose of study drug and had at least one post dose PK measurement.","reportingStatus":"POSTED","timeFrame":"Predose and 1 hour after start of infusion, end of injection (EOI) and 1 hour, 2 hours, 3 hours, 24 hours and 48 hours after EOI on Cycle 1 Day 29.","title":"Volume of Distribution at Steady State (Vss) of AFM13","type":"SECONDARY","unitOfMeasure":"Liter"}